

TransEnterix Announces Enhanced Capability to Perform Micro Incision Robotic Surgery

First-ever use of robotics to perform abdominal surgery with 3mm microlap instrumentation

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that surgeons have now performed the first 3mm micro laparoscopic robotic surgeries in the world utilizing the Senhance Surgical Robot. 3mm instruments, often referred to as micro laparoscopy, allow for surgeons to make tiny incisions that are deemed virtually scarless for patients.

The surgeries were performed at CHU Saint-Étienne in France, and at the Policlinico A. Gemelli Foundation in Rome, Italy. Professor Celine Chauleur and Dr. Salvatore Gueli Alletti, gynecologic oncologists, and Dr. Gabriele Barabino, a general surgeon, were the first surgeons in the world to utilize micro laparoscopic instruments with an abdominal robotic surgery platform. The surgeons successfully performed multiple cases in gynecologic and general surgery such as; ovarian cystectomy, endometrial excision, total laparoscopic hysterectomy, bilateral salpingo-oophorectomy and cholecystectomy utilizing robotic microlap instruments.

"Microlaparoscopy with robotic assistance is now a reality utilizing Senhance," said Todd M. Pope, President and CEO at TransEnterix. "The use of microlaparoscopy is a growing trend, but it can be challenging to manually control and stabilize such small instruments. We believe Senhance robotic assistance can enable surgeons to expand their use of virtually scarless surgery in more patients, and creates an additional way robotics can bring value over traditional manual approaches."

"Patients are consistently interested in the least invasive approach possible," said Dr. Barabino. "Utilizing 3mm microlap instruments with the Senhance Surgical Robot creates a virtually scarless approach with the precision of robotics to control such small instruments with delicate haptic force feedback."

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark, and is currently under FDA review for clearance in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Senhance robotic assistance can enable surgeons to expand their use of virtually scarless surgery in more patients, and creates an additional way robotics can bring value over traditional manual approaches. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 7, 2017 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For TransEnterix, Inc.

Investor Contact:

Mark Klausner, +1-443-213-0501

invest@transenterix.com

or

Media Contact:

(For EU) Conrad Harrington, +44 (0)20 3178 8914

(For US) Hannah Dunning, +1-415-618-8750

TransEnterix-SVC@sardverb.com

Source: TransEnterix, Inc.

News Provided by Acquire Media